Correction
for
Moser and Kalus, Ann Pharmacother 38 (12) 2094-2104.
Published Online, 14 December 2004, www.theannals.com, DOI 10.1345/aph.1E176a.
The Annals of Pharmacotherapy: Vol. 39, No. 1, pp. 201. DOI 10.1345/aph.1E176a
© 2005 Harvey Whitney Books Company.
Correction: Role of low-molecular-weight heparin in invasive management of nonST-elevation acute coronary syndromes
James S Kalus, PharmD BCPS
Assistant Professor Department of Pharmacy Practice Eugene Applebaum
College of Pharmacy and Health Sciences Wayne State University Detroit,
Michigan 48201-2427 fax 313/916-1302
jkalus{at}wayne.edu
Published Online, December 14, 2004. www.theannals.com, DOI 10.1345/aph.1E176a
TO THE EDITOR: In this recent article (2004;38:2094-104), the
enoxaparin bolus doses listed in Table 3 for both Ferguson trials (references
28 and 31) should be 0.3 mg/kg rather than 0.3 mg. Also, in the fourth
sentence of the first paragraph under the Implications for Clinical Practice
heading, the dose should be 0.3 mg/kg rather than 30 mg.